Regeneron Pharmaceuticals (REGN) said Tuesday it will boost its American manufacturing footprint by partnering with Fujifilm Diosynth Biotechnologies to produce biologics at a new North Carolina site.

The long-term agreement grants Regeneron access to Fujifilm's recently built biopharma facility in Holly Springs, the company said, nearly doubling its current large-scale manufacturing volume in the US.

The project, set to begin with an immediate technology transfer, represents a total investment of more than $3 billion over ten years, Regeneron said.

Regeneron said it is advancing multiple initiatives in New York, including a $3.6 billion expansion in Tarrytown, a fill-and-finish plant in Rensselaer, and a newly acquired property in Saratoga Springs for future growth.